Please login to the form below

Not currently logged in
Email:
Password:

Loxo Oncology

This page shows the latest Loxo Oncology news and features for those working in and with pharma, biotech and healthcare.

Roche undercuts price of Bayer cancer drug after winning FDA approval

Roche undercuts price of Bayer cancer drug after winning FDA approval

Vitrakvi, which Bayer acquired from Loxo Oncology, won approval in patients with NTRK gene fusions in November. ... Writing earlier this year, analysts at Jefferies called Rozlytrek one of Roche’s “lower risk late-stage key oncology assets”.

Latest news

  • CHMP backs Bayer’s tumour-agnostic drug Vitrakvi CHMP backs Bayer’s tumour-agnostic drug Vitrakvi

    Vitrakvi – originally developed by Loxo Oncology - was approved in the US for NTRK fusion tumours last November, and has also been given the green light in Canada and Brazil.

  • Roche’s rival to Bayer’s Vitrakvi gets speedy FDA review Roche’s rival to Bayer’s Vitrakvi gets speedy FDA review

    Entrectinib’s initial application in NTRK fusions sets it up in opposition to Bayer’s Vitrakvi follow-up LOXO-195, renamed BAY 2731954 after the German drugmaker took control of the ... two drugs in the wake of Eli Lilly’s $8bn acquisition of

  • EMA says Lilly’s Lartruvo should not be prescribed EMA says Lilly’s Lartruvo should not be prescribed

    The product was viewed as an important element in Lilly’s efforts to prop up its oncology franchise after the loss of patent protection for blockbuster Alimta (pemetrexed) in some markets, ... The company took a further step down the oncology-building

  • Pfizer takeover rumour ignites Amarin shares Pfizer takeover rumour ignites Amarin shares

    GlaxoSmithKline paid $5.1bn for Tesaro and its PARP inhibitor Zejula (niraparib) last month, and Eli Lilly snapping up Loxo Oncology for $8bn to claim its just-approved Vikrakvi (larotrectinib) for

  • Lilly adds to pharma M&A run with $8bn Loxo buy-out Lilly adds to pharma M&A run with $8bn Loxo buy-out

    platforms. Acquiring Loxo will help Lilly become a serious competitor in the immuno-oncology field, where it has had no presence until now. ... Loxo Oncology's portfolio of RET, BTK and TRK inhibitors targeted specifically to patients with mutations or

More from news
Approximately 1 fully matching, plus 16 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    Merck/MSD looks to have gained a dominant position in checkpoint inhibitor immuno-oncology (IO) with Keytruda – but there remains room for growth in the market via new IO agents. ... This is the first US product approval for Loxo Oncology and its

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    Following after the first generation of mainly antibody-based immuno-oncology drugs are a host of small-molecule drugs. ... also extending to targeted cancer drugs, with Loxo Oncology and Bayer’s larotrectinib filed for TRK gene fusion tumours and due

  • Deal Watch table for July 2013 Deal Watch table for July 2013

    485. Array BioPharma / Loxo Oncology. Multi-year licence and collaboration. Drug candidate (preclinical) discovery of small molecule drugs for oncology targets. ... 208. Talon Therapeutics / Spectrum Pharmaceuticals. Acquisition. Haemato-oncology

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare-focused, award-winning video production company which operates in the US and Europe. We create engaging visual...

Latest intelligence

Five key trends in precision and personalised healthcare
Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...
OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications
Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications...
Language barriers: Obesity has become a loaded word
...

Infographics